First-line serplulimab for advanced squamous non-small cell lung cancer: A multicenter, single-arm, real-world ASTRUM 004R study

被引：0
|
作者：
Shen, B. [1 ,2 ,3 ]
Yu, Z. [4 ]
Ding, H. [5 ]
Wang, H. [6 ]
Li, J. [7 ]
Xu, X. [8 ]
Tian, G. [9 ]
Han, G. [10 ]
Yin, L. [11 ]
Ji, Y. [12 ]
Zhou, Z. [13 ]
Zhou, L. [14 ]
Zhang, X. [15 ]
Sun, C. [16 ]
Ding, N. [17 ]
机构：
[1] Nanjing Med Univ, Jiangsu Canc Hosp, Med Oncol Dept, Nanjing, Peoples R China
[2] Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing, Peoples R China
[3] Nanjing Med Univ, Canc Hosp, Nanjing, Peoples R China
[4] Cent S Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China
[5] First Peoples Hosp Zhenjiang, Dept Respirat, Zhenjiang, Peoples R China
[6] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Oncol, Beijing, Peoples R China
[7] Wuhu Second Peoples Hosp, Dept Resp Med, Wuhu, Peoples R China
[8] Linyi Peoples Hosp, Dept Resp Med, Linyi, Peoples R China
[9] Jining Med Coll, Affiliated Hosp, Dept Resp Med, Jining, Peoples R China
[10] Taizhou Peoples Hosp, Dept Med Oncol, Taizhou, Peoples R China
[11] Dalian Med Univ, Affiliated Hosp 1, Dept Med Oncol, Dalian, Peoples R China
[12] Anyang Canc Hosp, Dept Internal Med, Anyang, South Korea
[13] First Peoples Hosp Yancheng, Dept Respirat, Yancheng, Peoples R China
[14] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Resp Med, Nanjing, Peoples R China
[15] Qingdao Cent Hosp, Dept Stereotact Radiotherapy, Qingdao 266000, Peoples R China
[16] Yangzhou Univ, Canc Inst, Northern Jiangsu Peoples Hosp, Coll Med, Yangzhou 255000, Jiangsu, Peoples R China
[17] Wuxi Huishan Dist Peoples Hosp, Oncol Dept, Wuxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.715
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
682P
引用
收藏
页码：S1660 / S1660
页数：1
相关论文
共 50 条
  • [31] Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations
    Pham Van Luan
    Nguyen Dinh Tien
    Nguyen Minh Hai
    Nguyen Dao Tien
    Thi Thi Duyen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [32] First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
    Wu, Y-L.
    Wang, Z.
    Dong, X.
    Li, J.
    Wu, L.
    Han, L.
    Li, X.
    Zang, A.
    Li, W.
    Wen, G.
    Lin, W.
    Feng, J.
    Wang, L.
    Li, J.
    Wang, Q.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1681 - S1681
  • [33] Atezolizumab plus chemotherapy followed by atezolizumab plus anlotinib in the first-line treatment for extensive-stage small cell lung cancer: A multicenter, single-arm, prospective real-world study
    Pan, Y.
    Qian, X.
    Zhou, H.
    Jin, W.
    Chen, J.
    Wang, Y.
    Zhang, Z.
    Liu, H.
    Jin, Y.
    Jiang, F.
    Liu, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1071 - S1071
  • [34] Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
    Shin, J. E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1696 - S1697
  • [35] Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial
    Chen, H.
    Hu, Y.
    Fan, Y.
    Wu, G.
    Cang, S.
    Yang, Y.
    Yang, N.
    Ma, R.
    Jing, G.
    Liu, A.
    Xu, X.
    Tang, S.
    Cheng, Y.
    Yu, Y.
    Wu, Y-L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S53 - S53
  • [36] Clinical observation of Pemetrexed first-line treatment in advanced non-squamous lung cancer or non-small cell lung cancer without driver-mutations: a phase 2, single-arm trial
    Sha, Zhou
    He, Jian-Bo
    Jiang, Qinling
    Xu, Linlin
    Hu, Liyang
    Liang, Zibin
    Li, Tin
    Lin, Zhong
    Yu, Qitao
    Pei, Xiaofeng
    Lv, Weize
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (20)
  • [37] Keeping it real: implications of real-world treatment outcomes for first-line immunotherapy in metastatic non-small cell lung cancer
    Hsu, Grace G.
    MacKay, Eric
    Scheuer, Nicolas
    Ramagopalan, Sreeram, V
    IMMUNOTHERAPY, 2021, 13 (18) : 1453 - 1456
  • [38] A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations
    Lei, Lei
    Wang, Wen-xian
    Yu, Zong-yang
    Liang, Xian-bin
    Pan, Wei-wei
    Chen, Hua-fei
    Wang, Li-ping
    Fang, Yong
    Wang, Min
    Xu, Chun-wei
    Fang, Mei-yu
    TRANSLATIONAL ONCOLOGY, 2020, 13 (02): : 329 - 335
  • [39] Atezolizumab in first-line treatment of metastatic nonsquamous non-small cell lung cancer in the real-world setting.
    De Castro, Javier
    Campos Balea, Begona
    Perez Parente, Diego
    Polito, Letizia
    Lawrance, Marcus
    Ruiz Gracia, Pedro
    Adler, Leah
    Marina Arroyo, Marta
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
    Lee, Sung Yong
    Choi, Chang-Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Choi, Juwhan
    Jang, Tae Won
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4353 - +
12345